Hepatitis Monthly

Published by: Kowsar

Nigella sativa and Non-Alcoholic Fatty Liver Disease: A Review of the Current Evidence

Mina Darand 1 , Seyed Moayed Alavian 2 and Azita Hekmatdoost 3 , *
Authors Information
1 Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Hepatitis Monthly: October 2018, 18 (10); e68046
  • Published Online: August 28, 2018
  • Article Type: Review Article
  • Received: February 26, 2018
  • Revised: May 29, 2018
  • Accepted: May 30, 2018
  • DOI: 10.5812/hepatmon.68046

To Cite: Darand M, Alavian S M, Hekmatdoost A. Nigella sativa and Non-Alcoholic Fatty Liver Disease: A Review of the Current Evidence, Hepat Mon. 2018 ; 18(10):e68046. doi: 10.5812/hepatmon.68046.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9-19. [PubMed: 19240815]. [PubMed Central: PMC2633261].
  • 2. Bagheri Lankarani K, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiria N, Heydari ST, et al. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013;13(5). doi: 10.5812/hepatmon.9248.
  • 3. Feridouni F, Geramizadeh B, Sepehrimanesh M, Safarpour AR, Fattahi MR. Histologically proved cytomegalovirus as a terrible and neglect disease: a 13-year report of gastrointestinal and hepatobiliary manifestations from single referral center. Comparat Clin Pathol. 2017;26(6):1253-7. doi: 10.1007/s00580-017-2516-1.
  • 4. Shamsdin SA, Sepehrimanesh M, Pezeshki B, Nejabat M. [Seroprevalence of hepatitis B and C in patients with hemophilia: a single-centre descriptive study]. Shiraz E-Med J. 2015;16(7). Persian. doi: 10.17795/semj24573.
  • 5. Sima H, Hekmatdoost A, Ghaziani T, Alavian SM, Mashayekh A, Zali MR. The prevalence of celiac autoantibodies in hepatitis patients. Iran J Allergy Asthma Immunol. 2010;9(3):157-62. [PubMed: 20952805].
  • 6. Mohamed WS, Mostafa AM, Mohamed KM, Serwah AH. Effects of fenugreek, Nigella, and termis seeds in nonalcoholic fatty liver in obese diabetic albino rats. Arab J Gastroenterol. 2015;16(1):1-9. doi: 10.1016/j.ajg.2014.12.003. [PubMed: 25670619].
  • 7. Jegatheesan P, De Bandt JP. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients. 2017;9(3). doi: 10.3390/nu9030230. [PubMed: 28273805]. [PubMed Central: PMC5372893].
  • 8. Xiao J, Ching YP, Liong EC, Nanji AA, Fung ML, Tipoe GL. Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model. Eur J Nutr. 2013;52(1):179-91. doi: 10.1007/s00394-012-0301-0. [PubMed: 22278044]. [PubMed Central: PMC3549410].
  • 9. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16(4):421-7. doi: 10.1097/01.mol.0000174153.53683.f2. [PubMed: 15990591].
  • 10. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330-44. doi: 10.1038/nrgastro.2013.41. [PubMed: 23507799].
  • 11. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metabol. 2008;34(6):634-7. doi: 10.1016/s1262-3636(08)74597-x.
  • 12. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103(2):71-83. doi: 10.1093/qjmed/hcp158. [PubMed: 19914930]. [PubMed Central: PMC2810391].
  • 13. Abbas AS, Abbasi MH, Malik IA, Sheikh N. Non-alcoholic fatty liver disease and associated changes in serum hepcidin, iron, ferritin-r levels and total iron binding capacity in weaning wistar rats (rattus norvegicus). J Anim Plant Sci. 2014;24(2):418-24.
  • 14. Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862-73. doi: 10.1016/j.jhep.2017.06.003.
  • 15. Fattahi MR, Niknam R, Safarpour A, Sepehrimanesh M, Lotfi M. The prevalence of metabolic syndrome in non-alcoholic fatty liver disease; a population-based study. Middle East J Dig Dis. 2016;8(2):131-7. doi: 10.15171/mejdd.2016.18. [PubMed: 27252820]. [PubMed Central: PMC4885612].
  • 16. Rojhani-Shirazi Z, Amini M, Meftahi N, Sepehrimanesh M, Poorbaghi SL, Vafa L. Comparison of anthropometric measures in people with and without short- and long-term complications after laparoscopic sleeve gastrectomy. Comparat Clin Pathol. 2017;26(6):1375-9. doi: 10.1007/s00580-017-2543-y.
  • 17. Heshmati J, Namazi N. Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: a systematic review. Complement Ther Med. 2015;23(2):275-82. doi: 10.1016/j.ctim.2015.01.013. [PubMed: 25847566].
  • 18. Mahdavi R, Heshmati J, Namazi N. Effects of black seeds (Nigella sativa) on male infertility: a systematic review. J Herb Med. 2015;5(3):133-9. doi: 10.1016/j.hermed.2015.03.002.
  • 19. Golparvar AR, Hadipanah A, Gheisari MM. Chemical analysis and identification of the components of two ecotypes of (Mentha Longifolia L.) in Iran province. Int J Agricult Crop Sci. 2013;5(17):1946.
  • 20. Shuid AN, Mohamed N, Mohamed IN, Othman F, Suhaimi F, Mohd Ramli ES, et al. Nigella sativa: a potential antiosteoporotic agent. Evidence-Based Complementary and Altern Med. 2012;2012.
  • 21. Toma CC, Olah NK, Vlase L, Mogosan C, Mocan A. Comparative studies on polyphenolic composition, antioxidant and diuretic effects of Nigella sativa L. (black cumin) and nigella damascena l. (lady-in-a-mist) seeds. Molecules. 2015;20(6):9560-74. doi: 10.3390/molecules20069560. [PubMed: 26016547].
  • 22. Mohammed NK, Manap A, Yazid M, Tan CP, Muhialdin BJ, Alhelli AM, et al. The effects of different extraction methods on antioxidant properties, chemical composition, and thermal behavior of black seed (Nigella sativa L.) oil. Evidence-Based Complementary and Altern Med. 2016;2016.
  • 23. Asgary S, Sahebkar A, Goli-Malekabadi N. Ameliorative effects of Nigella sativa on dyslipidemia. J Endocrinol Invest. 2015;38(10):1039-46. doi: 10.1007/s40618-015-0337-0. [PubMed: 26134064].
  • 24. Samir Bashandy AE. Effect of fixed oil of Nigella sativa on male fertility in normal and hyperlipidemic rats. Int J Pharmacol. 2007;3(1):27-33. doi: 10.3923/ijp.2007.27.33.
  • 25. Kooti W, Hasanzadeh-Noohi Z, Sharafi-Ahvazi N, Asadi-Samani M, Ashtary-Larky D. Phytochemistry, pharmacology, and therapeutic uses of black seed ( Nigella sativa ). Chinese J Natur Med. 2016;14(10):732-45. doi: 10.1016/s1875-5364(16)30088-7.
  • 26. Al-Jassir MS. Chemical composition and microflora of black cumin (Nigella sativa L.) seeds growing in Saudi Arabia. Food Chem. 1992;45(4):239-42. doi: 10.1016/0308-8146(92)90153-s.
  • 27. Khan MA. Chemical composition and medicinal properties of Nigella sativa Linn. Inflammopharmacology. 1999;7(1):15-35. doi: 10.1007/s10787-999-0023-y. [PubMed: 17657444].
  • 28. Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014;34(2):143-8. doi: 10.1016/j.nutres.2013.11.005. [PubMed: 24461315].
  • 29. Emamat H, Foroughi F, Eini-Zinab H, Hekmatdoost A. The effects of onion consumption on prevention of nonalcoholic fatty liver disease. India J Clin Biochem. 2018;33(1):75-80.
  • 30. Emamat H, Foroughi F, Eini-Zinab H, Taghizadeh M, Rismanchi M, Hekmatdoost A. The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease. J Diabetes Metab Disord. 2015;15:25. doi: 10.1186/s40200-016-0248-4. [PubMed: 27453880]. [PubMed Central: PMC4957858].
  • 31. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535-42. doi: 10.3945/ajcn.113.068890. [PubMed: 24401715].
  • 32. Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114(5):796-803. doi: 10.1017/S0007114515002433. [PubMed: 26234526].
  • 33. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837-43. doi: 10.1016/j.nutres.2014.09.005. [PubMed: 25311610].
  • 34. Ghaemi A, Taleban FA, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z, et al. How much weight loss is effective on nonalcoholic fatty liver disease? Hepat Mon. 2013;13(12). e15227. doi: 10.5812/hepatmon.15227. [PubMed: 24358045]. [PubMed Central: PMC3867211].
  • 35. Hekmatdoost A, Shamsipour A, Meibodi M, Gheibizadeh N, Eslamparast T, Poustchi H. Adherence to the dietary approaches to stop hypertension (dash) and risk of nonalcoholic fatty liver disease. Int J Food Sci Nutr. 2016;67(8):1024-9. doi: 10.1080/09637486.2016.1210101. [PubMed: 27436528].
  • 36. Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Brit J Nutrit. 2017;117(5):662-8. doi: 10.1017/s0007114517000204.
  • 37. Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr. 2017;8(2):240-52. doi: 10.3945/an.116.013151. [PubMed: 28298269]. [PubMed Central: PMC5347097].
  • 38. Mokhtari Z, Poustchi H, Eslamparast T, Hekmatdoost A. Egg consumption and risk of non-alcoholic fatty liver disease. World J Hepatol. 2017;9(10):503-9. doi: 10.4254/wjh.v9.i10.503. [PubMed: 28443155]. [PubMed Central: PMC5387362].
  • 39. Noori M, Jafari B, Hekmatdoost A. Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation. J Sci Food Agric. 2017;97(8):2327-32. doi: 10.1002/jsfa.8042. [PubMed: 27717115].
  • 40. Yari Z, Rahimlou M, Eslamparast T, Ebrahimi-Daryani N, Poustchi H, Hekmatdoost A. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. Int J Food Sci Nutr. 2016;67(4):461-9. doi: 10.3109/09637486.2016.1161011. [PubMed: 26983396].
  • 41. Kanter M, Akpolat M, Aktas C. Protective effects of the volatile oil of Nigella sativa seeds on beta-cell damage in streptozotocin-induced diabetic rats: a light and electron microscopic study. J Mol Histol. 2009;40(5-6):379-85. doi: 10.1007/s10735-009-9251-0. [PubMed: 20049514].
  • 42. Mansi KMS. Effects of oral administration of water extract of Nigella sativa on serum concentrations of insulin and testosterone in alloxan-induced diabetic rats. Pakistan J Biolog Sci. 2005;8(8):1152-6. doi: 10.3923/pjbs.2005.1152.1156.
  • 43. Tembhurne SV, Feroz S, More BH, Sakarkar DM. A review on therapeutic potential of Nigella sativa (kalonji) seeds. J Med Plants Res. 2014;8(3):167-77. doi: 10.5897/jmpr10.737.
  • 44. Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003;17(4):299-305. doi: 10.1002/ptr.1309. [PubMed: 12722128].
  • 45. Bai T, Lian LH, Wu YL, Wan Y, Nan JX. Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int Immunopharmacol. 2013;15(2):275-81. doi: 10.1016/j.intimp.2012.12.020. [PubMed: 23318601].
  • 46. Yang Y, Bai T, Yao YL, Zhang DQ, Wu YL, Lian LH, et al. Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury. Toxicol Lett. 2016;262:80-91. doi: 10.1016/j.toxlet.2016.09.014. [PubMed: 27688165].
  • 47. Sultan MT, Butt MS, Karim R, Iqbal SZ, Ahmad S, Zia-Ul-Haq M, et al. Effect of Nigella sativa fixed and essential oils on antioxidant status, hepatic enzymes, and immunity in streptozotocin induced diabetes mellitus. BMC Complement Altern Med. 2014;14:193. doi: 10.1186/1472-6882-14-193. [PubMed: 24939518]. [PubMed Central: PMC4077235].
  • 48. Meral I, Yener Z, Kahraman T, Mert N. Effect of Nigella sativa on glucose concentration, lipid peroxidation, anti-oxidant defence system and liver damage in experimentally-induced diabetic rabbits. J Vet Med A Physiol Pathol Clin Med. 2001;48(10):593-9. doi: 10.1046/j.1439-0442.2001.00393.x. [PubMed: 11848252].
  • 49. Awad AS, Abd Al Haleem EN, El-Bakly WM, Sherief MA. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(4):381-91. doi: 10.1007/s00210-015-1207-1. [PubMed: 26753695].
  • 50. Oguz S, Kanter M, Erboga M, Erenoglu C. Protective effects of thymoquinone against cholestatic oxidative stress and hepatic damage after biliary obstruction in rats. J Mol Histol. 2012;43(2):151-9. doi: 10.1007/s10735-011-9390-y. [PubMed: 22270828].
  • 51. Kong LY, Li GP, Yang P, Xi Z. Protective effect of thymoquinone on cholestatic rats with liver injury. Genet Mol Res. 2015;14(4):12247-53. doi: 10.4238/2015.October.9.13. [PubMed: 26505373].
  • 52. Najmi A, Nasiruddin M, Khan RA, Haque SF. Effect of Nigella sativa oil on various clinical and biochemical parameters of insulin resistance syndrome. Int J Diabetes Dev Ctries. 2008;28(1):11-4. doi: 10.4103/0973-3930.41980. [PubMed: 19902033]. [PubMed Central: PMC2772004].
  • 53. Hussain M, Tunio AG, Akhtar L, Shaikh GS. Effects of nigella sativa on various parameters in Patients of non-alcoholic fatty liver disease. J Ayub Med Coll Abbottabad. 2017;29(3):403-7. [PubMed: 29076670].
  • 54. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol. 2005;5(13-14):1749-70. doi: 10.1016/j.intimp.2005.06.008. [PubMed: 16275613].
  • 55. Badary OA, Taha RA, Gamal el-Din AM, Abdel-Wahab MH. Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol. 2003;26(2):87-98. doi: 10.1081/DCT-120020404. [PubMed: 12816394].
  • 56. Kaleem M, Kirmani D, Asif M, Ahmed Q, Bano B. Biochemical effects of Nigella sativa L seeds in diabetic rats. CSIR. 2006.
  • 57. Alimohammadi S, Hobbenaghi R, Javanbakht J, Kheradmand D, Mortezaee R, Tavakoli M, et al. Protective and antidiabetic effects of extract from Nigella sativa on blood glucose concentrations against streptozotocin (STZ)-induced diabetic in rats: an experimental study with histopathological evaluation. Diagn Pathol. 2013;8:137. doi: 10.1186/1746-1596-8-137. [PubMed: 23947821]. [PubMed Central: PMC3849825].
  • 58. Meddah B, Ducroc R, El Abbes Faouzi M, Eto B, Mahraoui L, Benhaddou-Andaloussi A, et al. Nigella sativa inhibits intestinal glucose absorption and improves glucose tolerance in rats. J Ethnopharmacol. 2009;121(3):419-24. doi: 10.1016/j.jep.2008.10.040. [PubMed: 19061948].
  • 59. Houcher Z, Boudiaf K, Benboubetra M, Houcher B. Effects of methanolic extract and commercial oil of Nigella sativa l. on blood glucose and antioxidant capacity in alloxan-induced diabetic rats. Pteridines. 2007;18(1). doi: 10.1515/pteridines.2007.18.1.8.
  • 60. Fararh KM, Ibrahim AK, Elsonosy YA. Thymoquinone enhances the activities of enzymes related to energy metabolism in peripheral leukocytes of diabetic rats. Res Vet Sci. 2010;88(3):400-4. doi: 10.1016/j.rvsc.2009.10.008. [PubMed: 19931880].
  • 61. Mohtashami A, Entezari MH. Effects of Nigella sativa supplementation on blood parameters and anthropometric indices in adults: a systematic review on clinical trials. J Res Med Sci. 2016;21:3. doi: 10.4103/1735-1995.175154. [PubMed: 27904549]. [PubMed Central: PMC5122217].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments